<DOC>
	<DOCNO>NCT00041639</DOCNO>
	<brief_summary>The purpose trial determine safety 90Y-hMN14 different dose level treatment pancreatic cancer .</brief_summary>
	<brief_title>Safety Study 90Y-hMN14 Treat Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>Disease Characteristics : Patients document histologic cytologic diagnosis pancreatic malignancy Patients recurrent , advance and/or metastatic disease , either fail standard therapy eligible alternate therapy higher therapeutic priority . Patients least one identify ( confirm ) measureable tumor site . Prior/Concurrent Therapy : Surgery : Patients exclude major surgery either within four week prior study entry . Chemotherapy : Patients must fail standard therapy eligible alternate therapy higher therapeutic priority . Biologic Therapy : Patients receive chimeric , CDRgrafted ( humanize ) , human IgG eligible provide prestudy evaluation demonstrate significant reactivity hMN14 IgG ( i.e. , HAHA ) Radiotherapy : No prior radiotherapy within four week study entry . No prior external beam irradiation field include 30 % red marrow . No prior radiation maximal tolerable level critical organ ( e.g. , 3,000 cGy liver ; 2,000 cGy lung kidney ) . Other : Any experimental therapy ( i.e. , drug , biologics , procedure ) primary malignancy , either within four week prior study entry . Patient Characteristics/ Performance Status : Patients Karnofsky performance status &gt; 70 % ( equivalent , ECOG 01 ) expect survival rate least 3 month Hematopoietic : Hemoglobin &gt; 10g/dL ; WBC &gt; 3000 per mm3 ; Granulocyte count &gt; 1500 per mm3 ; platelet count &gt; 100,000 per mm3 Hepatic : Total bilirubin &lt; 1.5 time institutional upper limit normal ( IULN ) ; AST ALT &lt; 2 X IULN Renal : Creatinine &lt; IULN Cardiovascular : Patients LVEF &gt; /= 50 % require MUGA/2DECHO study Pulmonary : Patients DF FEV1 &gt; /= 60 % require Pulmonary Function Tests Gastrointestinal : Patients severe anorexia related symptomology exclude Central Nervous System : Patient know metastatic disease CNS exclude Other : Patients prior image study murine antibody may include . Patients agree use medically effective method contraception period three month treatment period . A pregnancy test preform premenopausal female childbearing potential immediately prior entry study . Patients able understand give write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2004</verification_date>
	<keyword>Pancreatic Cancer</keyword>
	<keyword>Pancreatic Carcinoma</keyword>
	<keyword>Pancreatic Neoplasms</keyword>
	<keyword>Pancreas Cancer</keyword>
	<keyword>Pancreatic Tumor</keyword>
</DOC>